SAN DIEGO, May 8, 2023 /PRNewswire/ Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its. | May 8, 2023
Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Rating) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 22,200 shares, a decline of 12.9% from the March 31st total of 25,500 shares. Based on an average daily trading volume, of 25,900 shares, the days-to-cover ratio […]
SAN DIEGO, May 1, 2023 /PRNewswire/ Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its. | May 1, 2023
Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 25,500 shares, a growth of 390.4% from the March 15th total of 5,200 shares. Approximately 1.6% of the shares of the stock are sold short. Based on […]
Kintara Therapeutics, Inc. (NASDAQ:KTRA – Get Rating) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 25,500 shares, a growth of 390.4% from the March 15th total of 5,200 shares. Approximately 1.6% of the shares of the stock are sold short. Based on […]